Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
收藏数据链接：
官方服务：
资源简介：
Supplementary Table S1: Representativeness of Study Participants
创建时间：
2023-09-15
